Jilin Zhenao Pharmaceutical

Jilin Zhenao Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Jilin Sihuan Pharmaceutical Co., Ltd., which is a core backbone enterprise of Sihuan Pharmaceutical Holdings Group. Established in 2013 and located in Meihekou City, Jilin Province, the company is a national high-tech enterprise specializing in the R&D, manufacturing, and commercialization of small-volume injections. Its product portfolio includes Cerebroside Carnosine Injection (Oudimei) for cardiovascular and cerebrovascular diseases, Dopamine Hydrochloride Injection for shock syndrome, Ketorolac Tromethamine Injection, Phloroglucinol Injection, and Milrinone Injection. The company operates advanced, GMP-certified production lines for non-terminal and terminal sterilized small-volume injections, offering robust contract manufacturing (CMO) and technology transfer capabilities.